CA-LATTICEFLOW-AI
23.4.2024 09:01:32 CEST | Business Wire | Press release
LatticeFlow AI, the leading platform empowering Artificial Intelligence (AI) teams to build performant, safe, and trustworthy AI solutions, proudly announces that it has joined the U.S. AI Safety Institute Consortium (AISIC). LatticeFlow AI researchers will support Working Group #3, focusing on capability evaluations. Together with the National Institute of Standards & Technology (NIST) and other consortium members, LatticeFlow AI will support the development of methods, benchmarks, and testing environments that help organizations operationalize the practices outlined in NIST’s AI Risk Management Framework (RMF).
Dave Henry, SVP of Business Development at LatticeFlow AI, added: “AI safety programs are interdisciplinary in nature, requiring a broad range of management and technical skills to execute. The Consortium brings diverse experts together to create durable and innovative practices that promote trustworthy AI. We look forward to contributing our knowledge of AI model safety and collaborating on new approaches for scalable evaluations.”
Executive Demand for Trustworthy AI
Despite the impressive accuracy of AI models demonstrated in pilots and proof-of-concept projects, building AI solutions that perform reliably on real-world data remains an immense challenge. This affects both technical teams building and delivering AI solutions as well as management teams that need to quantify risks and approve AI solutions for use in business-critical operations. As a result, 85% of the models never make it into production, and out of those that do, 91% degrade over time.
“Unfortunately, high-value AI deployments are being delayed due to developer delay, insufficient good data governance and the inability to quantify possible risks associated with the use of their AI models,” stated Randolph Kahn Esq., President of Kahn Consulting Inc. “Consortiums such as AISIC can produce detailed guidelines and best practices, and when coupled with LatticeFlow AI’s technology, this can lead to a significant reduction of the time and cost required to complete thorough risk assessments and unlock the value of AI systems.”
The U.S. AI Safety Institute Consortium
AISIC was established by the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) to contribute to the priority actions outlined in U.S. President Biden’s Executive Order on the Safe, Secure, and Trustworthy Development and Use of AI. These include developing red-teaming guidelines, technical assessment standards, and risk management practices, among other key elements to the development of trustworthy AI and its responsible use.
LatticeFlow AI's Contributions to Making AI Safe and Trustworthy
LatticeFlow AI’s association with AISIC follows a series of contributions made by the LatticeFlow AI team towards the goals outlined by AISIC and President Biden’s Executive Order. Since 2020, LatticeFlow AI has been an invited technical contributor to key AI Safety initiatives at the International Organization for Standardization, where it has actively contributed to the working group focusing on the development and standards for Trustworthy AI. Earlier this year, LatticeFlow AI hosted renowned AI leaders at the World Economic Forum’s AI House, gathering key figures in AI, including Gary Marcus (NYU), Apostol Vassilev (NIST), Kai Zenner (European Parliament), Matthias Bossardt (KPMG), Thomas Stauner (BMW), among other industry experts, to delve into the latest AI developments and discuss responsible AI adoption.
From Standards to Practice: First AI Assessment for a Leading Swiss Bank
Moving beyond the development of AI guidelines and standards, this year, LatticeFlow AI announced the first industry-pioneering technical AI Assessment for Migros Bank, a leading Swiss Bank, demonstrating how these AI standards are used in practice to mitigate risk and ensure regulatory compliance for business-critical AI solutions. The results of this assessment, alongside a concrete blueprint to implement AI governance and technical AI assessments at enterprises and governments, were presented at a dedicated event hosted at the ETH AI Center.
LatticeFlow AI’s Commitment to the U.S. and NIST’s AI Safety Institute Consortium
With its contributions to AISIC, LatticeFlow AI will continue its commitment to helping U.S. government agencies such as the U.S. Army ensure the safety and trustworthiness of mission-critical AI systems. Last year, White House officials announced LatticeFlow AI as the first-place winner in the “red teaming” AI Privacy Prize Challenge category. Subsequently, the company announced a strategic expansion towards the US and a three-year strategic engagement with the U.S. Army to build next-generation resilient AI solutions for mission-critical defense use cases.
"Joining AISIC will allow us to accelerate and broaden our impact by aligning our efforts towards ensuring AI trust and safety with global AI leaders, enterprises, and governments," said Petar Tsankov, Co-founder and CEO of LatticeFlow AI.
Interested in learning more?
- Watch the replay of our event on AI Governance & Audits: Navigating AI Risks and Compliance.
- Visit our web page to learn how to manage your AI model risk with comprehensive technical AI assessments.
- If you are interested in conducting an AI assessment, book a meeting with a LatticeFlow AI expert.
About LatticeFlow AI
LatticeFlow AI offers a cutting edge AI platform that empowers enterprise teams to build performant, safe, and trustworthy AI at scale. Our platform is designed to unlock the full value of AI by systematically addressing critical model and data issues through automated processes and intelligent workflows across your entire AI lifecycle.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423153331/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
